FDA approves Moderna RSV vaccine for seniors
FDA approves Moderna RSV vaccine for seniors
FDA Approves Moderna's RSV Vaccine for Seniors
Moderna's Second Product Hits the Market
The FDA has approved Moderna's RSV vaccine, mRESVIA, for adults aged 60 and above, marking it as the company's second product in the U.S. market.
Revenue Boost for Moderna
This approval is crucial for Moderna as it seeks new revenue streams, especially with the declining demand for its COVID-19 vaccine.
Unique Features of mRESVIA
mRESVIA is the first mRNA vaccine for a disease other than COVID-19 and is uniquely available in a pre-filled syringe for easier administration.
Pending CDC Recommendations
A CDC advisory panel is set to vote in June on the usage recommendations for mRESVIA, which could influence its market competition against similar RSV vaccines from GSK and Pfizer.
Versatility of mRNA Technology
The approval underscores the potential of Moderna's mRNA technology, which is being used to develop treatments for various diseases, including cancer and norovirus.
How does Moderna's RSV vaccine differ from its previous products in terms of administration?
Moderna's RSV vaccine, mRESVIA, is the first messenger RNA vaccine approved for a disease other than COVID-19. It is also the only RSV vaccine available in a pre-filled syringe. This design aims to make the vaccine easier to administer to patients.